An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

Condition(s) targeted: Gaucher Disease, Type 1

Intervention: velaglucerase alfa (Biological)

Phase: Phase 3

Status: Recruiting

Sponsored by: Shire Human Genetic Therapies, Inc.

Official(s) and/or principal investigator(s):
Eric Crombez, M.D., Study Director, Affiliation: Shire Human Genetic Therapies, Inc.

Overall contact:
Tiffany Crump, Phone: 484-595-8850, Email: tcrump@shire.com

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the long-term safety of every other week dosing of Gene-Activated® human glucocerebrosidase (GA-GCB, velaglucerase alfa) intravenously in patients with type 1 Gaucher disease.

Official title: An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety Study

Primary outcome: Evaluation of safety assessments

Secondary outcome: The evaluation of hematological parameters and organomegaly

Detailed description: Type 1 Gaucher disease, the most common form,accounts for more than 90% of all cases and does not involve the CNS. Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB,velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. GA-GCB contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the long-term safety of GA-GCB in men, women, and children with Type 1 Gaucher disease.

Minimum age: 2 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. The patient has completed study TKT032 or TKT034, or study HGT-GCB-039.

2. Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study.

3. Male patients must agree to use a medically acceptable method of contraception at all times during the study and report a partner's pregnancy to the investigator.

4. The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).

5. The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator

Exclusion Criteria:

1. The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted.

2. The patient is pregnant or lactating.

3. The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.

4. The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e. g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.).

5. The patient is unable to comply with the protocol, e. g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator

Tiffany Crump, Phone: 484-595-8850, Email: tcrump@shire.com

Shaare Zedek Medical Center, Jerusalem 91031, Israel; Recruiting
Deborah Elstein, Ph.D., Phone: 972-54-572828, Email: elstein@szmc.org.il
Ari Zimran, M.D., Principal Investigator

Sociedad Espanola de Socorros Mutuos, Asuncion, Paraguay; Recruiting
Ana Iris Benitez, Phone: (595)21-420.888299.122, Email: iris@webmail.pla.net.py
Derlis Gonzalez, MD, Principal Investigator

Starting date: March 2008
Ending date: December 2014
Last updated: July 31, 2008